Evidence map›Paper›PMID 39734710›Full record

ArticleTherapeutic advances in medical oncology2024

Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations.

Nadia Ghazali, Jamie Feng, Katrina Hueniken, Khaleeq Khan, Karmugi Balaratnam, Thomas K Waddell, Kazuhiro Yasufuku, Andrew Pierre, Laura Donahoe, Elliot Wakeam and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in medical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Nadia GhazaliDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre (PMCC), University Health Network (UHN), Toronto, ON, Canada.ORCID https://orcid.org/0000-0002-4824-5061
Jamie FengDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre (PMCC), University Health Network (UHN), Toronto, ON, Canada.
Katrina HuenikenDepartment of Biostatistics, PMCC, UHN, Toronto, ON, Canada.
Khaleeq KhanDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre (PMCC), University Health Network (UHN), Toronto ON, Canada.
Karmugi BalaratnamDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre (PMCC), University Health Network (UHN), Toronto ON, Canada.
Thomas K WaddellDivision of Thoracic Surgery, UHN, Toronto, ON, Canada.
Kazuhiro YasufukuDivision of Thoracic Surgery, UHN, Toronto, ON, Canada.
Andrew PierreDivision of Thoracic Surgery, UHN, Toronto, ON, Canada.
Laura DonahoeDivision of Thoracic Surgery, UHN, Toronto, ON, Canada.
Elliot WakeamDivision of Thoracic Surgery, UHN, Toronto, ON, Canada.
Marcelo CypelDivision of Thoracic Surgery, UHN, Toronto, ON, Canada.
Jonathan YeungDivision of Thoracic Surgery, UHN, Toronto, ON, Canada.
Shaf KeshavjeeDivision of Thoracic Surgery, UHN, Toronto, ON, Canada.
Marc de PerrotDivision of Thoracic Surgery, UHN, Toronto, ON, Canada.
Natasha B LeighlDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre (PMCC), University Health Network (UHN), Toronto, ON, Canada.
Geoffrey LiuDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre (PMCC), University Health Network (UHN), Toronto, ON, Canada.
Penelope A BradburyDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre (PMCC), University Health Network (UHN), Toronto, ON, Canada.
Adrian SacherDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre (PMCC), University Health Network (UHN), Toronto, ON, Canada.
Lawson EngDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre (PMCC), University Health Network (UHN), Toronto, ON, Canada.
Tracy StockleyLaboratory Medicine Program, UHN, Toronto, ON, Canada.
Ming Sound TsaoDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre (PMCC), University Health Network (UHN), 700 University Avenue, 7-812, Toronto, ON M5G 2M9, Canada.ORCID https://orcid.org/0000-0002-9160-5405
Frances A ShepherdDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre (PMCC), University Health Network (UHN), 700 University Avenue, 7-812, Toronto, ON M5G 2M9, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Given advancements in adjuvant treatments for non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK)-targeted therapies, it is important to consider postoperative targeted therapies for other early-stage oncogene-addicted NSCLC. Exploring baseline outcomes for early-stage NSCLC with these rare mutations is crucial. Objectives: This study aims to assess relapse-free survival (RFS) and overall survival (OS) in patients with resected early-stage NSCLC with rare targetable driver mutations. Methods: This retrospective single-center study identified stage I-III NSCLC patients with rare targetable mutations who underwent curative surgery. Tissue-based molecular profiling identified mutations in Results: Among 225 patients, mutations included the following: Conclusion: While RFS was poorer for most mutations compared to

Indexed as

actionable genomic alterationearly-stagenon-small-cell lung cancerrare driver mutationsurgery

Identifiers

PMID39734710
PMCPMC11672496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.